Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
28
MESO Quote, Financials, Valuation and Earnings
Last price:
$14.81
Seasonality move
:
2.08%
Day range:
$14.74 - $15.27
52-week range:
$9.61 - $21.50
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
27.18x
P/B ratio:
3.54x
Volume:
173.2K
Avg. volume:
304.8K
1-year change:
25.3%
Market cap:
$1.8B
Revenue:
$17.2M
EPS (TTM):
-$0.74
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
MESO
Mesoblast Ltd.
|
$33.2M | -- | -100% | -- | $35.00 |
|
CSLLY
CSL Ltd.
|
-- | -- | -- | -- | -- |
|
IMMP
Immutep Ltd.
|
-- | -- | -- | -- | $1.00 |
|
KZIA
Kazia Therapeutics Ltd.
|
-- | -- | -- | -- | $18.94 |
|
LVCLF
Algorae Pharmaceuticals Ltd.
|
-- | -- | -- | -- | -- |
|
SPHRY
Starpharma Holdings Ltd.
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
MESO
Mesoblast Ltd.
|
$14.81 | $35.00 | $1.8B | -- | $0.00 | 0% | 27.18x |
|
CSLLY
CSL Ltd.
|
$24.20 | -- | $22.9B | 33.70x | $0.33 | 3.09% | 3.08x |
|
IMMP
Immutep Ltd.
|
$0.36 | $1.00 | $51.8M | -- | $0.00 | 0% | 19.50x |
|
KZIA
Kazia Therapeutics Ltd.
|
$7.34 | $18.94 | $85.5M | -- | $0.00 | 0% | 657.43x |
|
LVCLF
Algorae Pharmaceuticals Ltd.
|
$0.0079 | -- | $13.5M | -- | $0.00 | 0% | 0.14x |
|
SPHRY
Starpharma Holdings Ltd.
|
$3.25 | -- | $133.9M | -- | $0.00 | 0% | 14.86x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
MESO
Mesoblast Ltd.
|
-- | 0.902 | -- | -- |
|
CSLLY
CSL Ltd.
|
39.2% | 0.336 | -- | 0.84x |
|
IMMP
Immutep Ltd.
|
-- | 5.385 | -- | -- |
|
KZIA
Kazia Therapeutics Ltd.
|
-6.76% | 2.871 | -- | 0.07x |
|
LVCLF
Algorae Pharmaceuticals Ltd.
|
-- | -2.358 | -- | -- |
|
SPHRY
Starpharma Holdings Ltd.
|
9.65% | 2.775 | -- | 4.93x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
MESO
Mesoblast Ltd.
|
-- | -- | -- | -- | -- | -- |
|
CSLLY
CSL Ltd.
|
$4.3B | $2B | 8.85% | 14.06% | 33.52% | -- |
|
IMMP
Immutep Ltd.
|
-- | -- | -- | -- | -- | -- |
|
KZIA
Kazia Therapeutics Ltd.
|
-- | -- | -784.09% | -1083.16% | -- | -- |
|
LVCLF
Algorae Pharmaceuticals Ltd.
|
-- | -- | -- | -- | -- | -- |
|
SPHRY
Starpharma Holdings Ltd.
|
-- | -- | -40.48% | -43.48% | -- | -- |
Mesoblast Ltd. vs. Competitors
-
Which has Higher Returns MESO or CSLLY?
CSL Ltd. has a net margin of -- compared to Mesoblast Ltd.'s net margin of 24.44%. Mesoblast Ltd.'s return on equity of -- beat CSL Ltd.'s return on equity of 14.06%.
Company Gross Margin Earnings Per Share Invested Capital MESOMesoblast Ltd.-- -- -- CSLLYCSL Ltd.52.1% $2.07 $32.5B -
What do Analysts Say About MESO or CSLLY?
Mesoblast Ltd. has a consensus price target of $35.00, signalling upside risk potential of 136.33%. On the other hand CSL Ltd. has an analysts' consensus of -- which suggests that it could fall by --. Given that Mesoblast Ltd. has higher upside potential than CSL Ltd., analysts believe Mesoblast Ltd. is more attractive than CSL Ltd..
Company Buy Ratings Hold Ratings Sell Ratings MESOMesoblast Ltd.1 0 0 CSLLYCSL Ltd.0 0 0 -
Is MESO or CSLLY More Risky?
Mesoblast Ltd. has a beta of 2.193, which suggesting that the stock is 119.292% more volatile than S&P 500. In comparison CSL Ltd. has a beta of 0.802, suggesting its less volatile than the S&P 500 by 19.819%.
-
Which is a Better Dividend Stock MESO or CSLLY?
Mesoblast Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CSL Ltd. offers a yield of 3.09% to investors and pays a quarterly dividend of $0.33 per share. Mesoblast Ltd. pays -- of its earnings as a dividend. CSL Ltd. pays out 43.93% of its earnings as a dividend. CSL Ltd.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios MESO or CSLLY?
Mesoblast Ltd. quarterly revenues are --, which are smaller than CSL Ltd. quarterly revenues of $8.2B. Mesoblast Ltd.'s net income of -- is lower than CSL Ltd.'s net income of $2B. Notably, Mesoblast Ltd.'s price-to-earnings ratio is -- while CSL Ltd.'s PE ratio is 33.70x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Mesoblast Ltd. is 27.18x versus 3.08x for CSL Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MESOMesoblast Ltd.27.18x -- -- -- CSLLYCSL Ltd.3.08x 33.70x $8.2B $2B
-
Which has Higher Returns MESO or IMMP?
Immutep Ltd. has a net margin of -- compared to Mesoblast Ltd.'s net margin of --. Mesoblast Ltd.'s return on equity of -- beat Immutep Ltd.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital MESOMesoblast Ltd.-- -- -- IMMPImmutep Ltd.-- -- -- -
What do Analysts Say About MESO or IMMP?
Mesoblast Ltd. has a consensus price target of $35.00, signalling upside risk potential of 136.33%. On the other hand Immutep Ltd. has an analysts' consensus of $1.00 which suggests that it could grow by 176.63%. Given that Immutep Ltd. has higher upside potential than Mesoblast Ltd., analysts believe Immutep Ltd. is more attractive than Mesoblast Ltd..
Company Buy Ratings Hold Ratings Sell Ratings MESOMesoblast Ltd.1 0 0 IMMPImmutep Ltd.0 1 0 -
Is MESO or IMMP More Risky?
Mesoblast Ltd. has a beta of 2.193, which suggesting that the stock is 119.292% more volatile than S&P 500. In comparison Immutep Ltd. has a beta of 2.158, suggesting its more volatile than the S&P 500 by 115.754%.
-
Which is a Better Dividend Stock MESO or IMMP?
Mesoblast Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Immutep Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Mesoblast Ltd. pays -- of its earnings as a dividend. Immutep Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MESO or IMMP?
Mesoblast Ltd. quarterly revenues are --, which are smaller than Immutep Ltd. quarterly revenues of --. Mesoblast Ltd.'s net income of -- is lower than Immutep Ltd.'s net income of --. Notably, Mesoblast Ltd.'s price-to-earnings ratio is -- while Immutep Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Mesoblast Ltd. is 27.18x versus 19.50x for Immutep Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MESOMesoblast Ltd.27.18x -- -- -- IMMPImmutep Ltd.19.50x -- -- --
-
Which has Higher Returns MESO or KZIA?
Kazia Therapeutics Ltd. has a net margin of -- compared to Mesoblast Ltd.'s net margin of --. Mesoblast Ltd.'s return on equity of -- beat Kazia Therapeutics Ltd.'s return on equity of -1083.16%.
Company Gross Margin Earnings Per Share Invested Capital MESOMesoblast Ltd.-- -- -- KZIAKazia Therapeutics Ltd.-- -- -$6.3M -
What do Analysts Say About MESO or KZIA?
Mesoblast Ltd. has a consensus price target of $35.00, signalling upside risk potential of 136.33%. On the other hand Kazia Therapeutics Ltd. has an analysts' consensus of $18.94 which suggests that it could grow by 159.8%. Given that Kazia Therapeutics Ltd. has higher upside potential than Mesoblast Ltd., analysts believe Kazia Therapeutics Ltd. is more attractive than Mesoblast Ltd..
Company Buy Ratings Hold Ratings Sell Ratings MESOMesoblast Ltd.1 0 0 KZIAKazia Therapeutics Ltd.1 0 0 -
Is MESO or KZIA More Risky?
Mesoblast Ltd. has a beta of 2.193, which suggesting that the stock is 119.292% more volatile than S&P 500. In comparison Kazia Therapeutics Ltd. has a beta of 1.612, suggesting its more volatile than the S&P 500 by 61.208%.
-
Which is a Better Dividend Stock MESO or KZIA?
Mesoblast Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Kazia Therapeutics Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Mesoblast Ltd. pays -- of its earnings as a dividend. Kazia Therapeutics Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MESO or KZIA?
Mesoblast Ltd. quarterly revenues are --, which are smaller than Kazia Therapeutics Ltd. quarterly revenues of --. Mesoblast Ltd.'s net income of -- is lower than Kazia Therapeutics Ltd.'s net income of --. Notably, Mesoblast Ltd.'s price-to-earnings ratio is -- while Kazia Therapeutics Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Mesoblast Ltd. is 27.18x versus 657.43x for Kazia Therapeutics Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MESOMesoblast Ltd.27.18x -- -- -- KZIAKazia Therapeutics Ltd.657.43x -- -- --
-
Which has Higher Returns MESO or LVCLF?
Algorae Pharmaceuticals Ltd. has a net margin of -- compared to Mesoblast Ltd.'s net margin of --. Mesoblast Ltd.'s return on equity of -- beat Algorae Pharmaceuticals Ltd.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital MESOMesoblast Ltd.-- -- -- LVCLFAlgorae Pharmaceuticals Ltd.-- -- -- -
What do Analysts Say About MESO or LVCLF?
Mesoblast Ltd. has a consensus price target of $35.00, signalling upside risk potential of 136.33%. On the other hand Algorae Pharmaceuticals Ltd. has an analysts' consensus of -- which suggests that it could fall by --. Given that Mesoblast Ltd. has higher upside potential than Algorae Pharmaceuticals Ltd., analysts believe Mesoblast Ltd. is more attractive than Algorae Pharmaceuticals Ltd..
Company Buy Ratings Hold Ratings Sell Ratings MESOMesoblast Ltd.1 0 0 LVCLFAlgorae Pharmaceuticals Ltd.0 0 0 -
Is MESO or LVCLF More Risky?
Mesoblast Ltd. has a beta of 2.193, which suggesting that the stock is 119.292% more volatile than S&P 500. In comparison Algorae Pharmaceuticals Ltd. has a beta of -0.492, suggesting its less volatile than the S&P 500 by 149.15%.
-
Which is a Better Dividend Stock MESO or LVCLF?
Mesoblast Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Algorae Pharmaceuticals Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Mesoblast Ltd. pays -- of its earnings as a dividend. Algorae Pharmaceuticals Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MESO or LVCLF?
Mesoblast Ltd. quarterly revenues are --, which are smaller than Algorae Pharmaceuticals Ltd. quarterly revenues of --. Mesoblast Ltd.'s net income of -- is lower than Algorae Pharmaceuticals Ltd.'s net income of --. Notably, Mesoblast Ltd.'s price-to-earnings ratio is -- while Algorae Pharmaceuticals Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Mesoblast Ltd. is 27.18x versus 0.14x for Algorae Pharmaceuticals Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MESOMesoblast Ltd.27.18x -- -- -- LVCLFAlgorae Pharmaceuticals Ltd.0.14x -- -- --
-
Which has Higher Returns MESO or SPHRY?
Starpharma Holdings Ltd. has a net margin of -- compared to Mesoblast Ltd.'s net margin of --. Mesoblast Ltd.'s return on equity of -- beat Starpharma Holdings Ltd.'s return on equity of -43.48%.
Company Gross Margin Earnings Per Share Invested Capital MESOMesoblast Ltd.-- -- -- SPHRYStarpharma Holdings Ltd.-- -- $15.9M -
What do Analysts Say About MESO or SPHRY?
Mesoblast Ltd. has a consensus price target of $35.00, signalling upside risk potential of 136.33%. On the other hand Starpharma Holdings Ltd. has an analysts' consensus of -- which suggests that it could fall by --. Given that Mesoblast Ltd. has higher upside potential than Starpharma Holdings Ltd., analysts believe Mesoblast Ltd. is more attractive than Starpharma Holdings Ltd..
Company Buy Ratings Hold Ratings Sell Ratings MESOMesoblast Ltd.1 0 0 SPHRYStarpharma Holdings Ltd.0 0 0 -
Is MESO or SPHRY More Risky?
Mesoblast Ltd. has a beta of 2.193, which suggesting that the stock is 119.292% more volatile than S&P 500. In comparison Starpharma Holdings Ltd. has a beta of 0.797, suggesting its less volatile than the S&P 500 by 20.334%.
-
Which is a Better Dividend Stock MESO or SPHRY?
Mesoblast Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Starpharma Holdings Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Mesoblast Ltd. pays -- of its earnings as a dividend. Starpharma Holdings Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MESO or SPHRY?
Mesoblast Ltd. quarterly revenues are --, which are smaller than Starpharma Holdings Ltd. quarterly revenues of --. Mesoblast Ltd.'s net income of -- is lower than Starpharma Holdings Ltd.'s net income of --. Notably, Mesoblast Ltd.'s price-to-earnings ratio is -- while Starpharma Holdings Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Mesoblast Ltd. is 27.18x versus 14.86x for Starpharma Holdings Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MESOMesoblast Ltd.27.18x -- -- -- SPHRYStarpharma Holdings Ltd.14.86x -- -- --
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Sell
46
Is NVDA Stock a Buy?
Market Cap: $4.3T
P/E Ratio: 36x
Sell
50
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 34x
Sell
40
Is GOOGL Stock a Buy?
Market Cap: $3.6T
P/E Ratio: 27x
Alerts
Buy
51
AAOI alert for Apr 3
Applied Optoelectronics, Inc. [AAOI] is up 20.3% over the past day.
Buy
59
SBAC alert for Apr 3
SBA Communications Corp. [SBAC] is up 18.96% over the past day.
Buy
55
VSAT alert for Apr 3
ViaSat, Inc. [VSAT] is up 18.73% over the past day.
